Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Transdermal Radiofrequency (V ERASER) Versus Polidocanol Sclerotherapy for the Treatment of Reticular Veins and Telangiectasias: A Randomized Controlled Trial (TYPER Trial)

NCT06962813 is registered in ClinicalTrials.gov with Science Valley Research Institute as lead sponsor.

NCT NCT06962813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06962813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Transdermal Radiofrequency (V ERASER) Versus Polidocanol Sclerotherapy for the Treatment of Reticular Veins and Telangiectasias: A Randomized Controlled Trial (TYPER Trial)
Lead sponsor
Science Valley Research Institute
Phase
Not applicable
Overall status
Completed
Start date
January 10, 2023
Completion date
April 10, 2025
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

telangiectasias, varicose veins leg